Affinage

AMELX

Amelogenin, X isoform · UniProt Q99217

Length
191 aa
Mass
21.6 kDa
Annotated
2026-06-09
100 papers in source corpus 7 papers cited in narrative 7 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 5/5 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

AMELX encodes amelogenin, an enamel matrix protein with a direct, non-redundant role in the biomineralization of tooth enamel (PMID:1916828, PMID:27896287). Amelogenin secreted by ameloblasts organizes enamel ribbon development, drives thickening of the enamel layer, and facilitates conversion of the initial octacalcium phosphate mineral into hydroxyapatite; in Amelx-null enamel the layer is markedly thinned, ribbons fuse into plates, hardness is reduced, and octacalcium phosphate persists as the predominant mineral (PMID:27896287). Normal function depends on the conserved tri-tyrosyl domain, where a Y→H substitution blocks secretion of full-length amelogenin, causing ER/Golgi engorgement, ameloblast apoptosis, and severe mineralization defects, and where the same motif mediates protein-protein interactions implicated in cytotoxicity when co-expressed with ameloblastin (Ambn) (PMID:20067920). Function also requires the precise repertoire of AMELX alternative splicing: a silent exon 4 variant that forces inclusion of the normally skipped exon 4 disrupts the isoform ratio and produces enamel mineralization defects (PMID:25117480). Loss-of-function lesions — large deletions, frameshift/nonsense mutations, and missense changes in conserved residues such as codon 41 — cause X-linked amelogenesis imperfecta with defects in enamel thickness, mineralization, and prism organization (PMID:1916828, PMID:1483698, PMID:11005731); the codon 41 mutation specifically causes retention of amelogenin within crystallites and abnormal crystallite morphology, establishing this residue as critical for matrix organization (PMID:11005731).

Mechanistic history

Synthesis pass · year-by-year structured walk · 7 steps
  1. 1991 High

    Established that AMELX itself is required for enamel biomineralization by linking a large gene deletion to the hypomineralization form of X-linked amelogenesis imperfecta.

    Evidence Southern blot, PCR, and segregation analysis across 15 individuals in a kindred

    PMID:1916828

    Open questions at the time
    • Does not define which protein domains or functions are lost
    • No molecular mechanism of how amelogenin organizes mineral
  2. 1992 Medium

    Showed amelogenin is required for both enamel thickness and mineralization, not just one, by tying a frameshift/premature-stop mutation to a combined hypoplasia and hypomineralization phenotype.

    Evidence DNA sequencing and PCR of AMELX exons with clinical phenotyping in an AI family

    PMID:1483698

    Open questions at the time
    • Single family, single lab
    • Does not distinguish secretion failure from downstream matrix dysfunction
  3. 1995 Medium

    Demonstrated extensive allelic heterogeneity in AMELX-linked amelogenesis imperfecta, reinforcing the gene's causal role across multiple distinct mutations.

    Evidence SSCP analysis and DNA sequencing in three AI families

    PMID:7599636

    Open questions at the time
    • No functional characterization of the individual variants
    • Genotype-phenotype correlation not resolved at protein level
  4. 2000 High

    Identified a single conserved residue (codon 41) whose substitution disrupts matrix organization, showing amelogenin must reside in inter-crystalline spaces rather than be retained within crystallites for normal enamel.

    Evidence PCR/sequencing plus light/SEM/TEM microscopy, anti-amelogenin immunolocalization, and amino acid analysis in three families

    PMID:11005731

    Open questions at the time
    • Mechanism by which codon 41 controls protein partitioning unknown
    • Does not address splicing or secretion
  5. 2010 High

    Defined a secretion-failure mechanism: the tri-tyrosyl domain is needed for ameloblasts to secrete full-length amelogenin, and its disruption causes ER/Golgi engorgement, apoptosis, and possibly toxic interactions with ameloblastin.

    Evidence Mouse Amelx Y→H genetic model with immunohistochemistry and co-transfection with Ambn in a eukaryotic cell line

    PMID:20067920

    Open questions at the time
    • Direct binding between amelogenin and ameloblastin not biochemically demonstrated
    • Contribution of cell death versus matrix loss to phenotype not separated
  6. 2014 High

    Established that the conserved AMELX alternative-splicing pattern itself is functionally required, since forcing inclusion of normally skipped exon 4 disrupts isoform balance and causes mineralization defects.

    Evidence Human mutation identification, mRNA splice analysis, and transgenic animal modeling

    PMID:25117480

    Open questions at the time
    • Distinct functional roles of individual isoforms not defined
    • How altered isoform ratio impairs mineralization at molecular level unclear
  7. 2016 High

    Resolved amelogenin's structural and chemical role in enamel: it thickens the layer, organizes ribbon separation, and drives conversion of octacalcium phosphate to hydroxyapatite, with dose-dependent (lyonization) effects.

    Evidence Amelx knockout/heterozygous mouse model with RT-PCR, Western blot, IHC, TEM/SEM, nanohardness testing, and X-ray diffraction

    PMID:27896287

    Open questions at the time
    • Molecular mechanism of OCP-to-HAP conversion not defined
    • Direct biochemical interaction of amelogenin with mineral surfaces not characterized

Open questions

Synthesis pass · forward-looking unresolved questions
  • How amelogenin physically couples to other matrix proteins and mineral surfaces to template crystal growth, and the discrete functional division between its splice isoforms, remain unresolved.
  • No direct structural model of amelogenin-mineral or amelogenin-ameloblastin interaction in the corpus
  • Isoform-specific functions not assigned

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0005198 structural molecule activity 2
Localization
GO:0005576 extracellular region 2 GO:0031012 extracellular matrix 2 GO:0005783 endoplasmic reticulum 1
Pathway
R-HSA-1266738 Developmental Biology 2 R-HSA-1474244 Extracellular matrix organization 2
Partners

Evidence

Reading pass · 7 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1991 A deletion extending over 5 kb of the amelogenin gene (AMELX/AMG) was identified in males with the hypomineralization form of X-linked amelogenesis imperfecta (AIH1), establishing that AMELX encodes a protein with a direct role in biomineralization of tooth enamel. Southern blot analysis, PCR analysis, segregation analysis in 15 individuals Genomics High 1916828
1992 A nonsense mutation (single base deletion in exon 5 causing frameshift and premature TGA stop codon) in AMELX was identified in an X-linked amelogenesis imperfecta family, resulting in both enamel hypoplasia and hypomineralization, indicating amelogenin is required for both normal enamel thickness and mineralization. DNA sequencing, PCR amplification of AMELX exons, clinical phenotyping Human genetics Medium 1483698
1995 Three novel AMELX mutations were identified in X-linked amelogenesis imperfecta families: a C-T substitution in exon 5, a G-T substitution in exon 6, and a single cytosine deletion in exon 6, confirming extensive allelic heterogeneity and the direct role of AMELX in enamel biomineralization. Single-strand conformational polymorphism (SSCP) analysis and DNA sequencing Human mutation Medium 7599636
2000 A specific AMELX point mutation (C to A at codon 41) in a highly conserved region results in a consistent enamel phenotype: opaque enamel with prism defects, morphologically abnormal crystallites, retention of amelogenin protein within crystallites (not inter-crystalline spaces), and increased amelogenin-like protein content (0.95% vs 0.13% normal). This demonstrates that codon 41 encodes a residue critical for normal amelogenin function in enamel matrix organization. Mutational analysis by PCR and sequencing; light, scanning, and transmission electron microscopy; immunolocalization with anti-amelogenin antibodies; amino acid analysis Journal of dental research High 11005731
2010 A missense mutation (Y→H substitution) in the tri-tyrosyl domain of mouse Amelx causes failure of ameloblasts to secrete full-length amelogenin, leading to engorgement of the ER/Golgi apparatus, increased ameloblast apoptosis, and severe enamel biomineralization defects. Co-transfection of mutant Amelx with Ambn in a eukaryotic cell line revealed intracellular abnormalities and increased cytotoxicity, suggesting protein-protein interactions mediated via the amelogenin tri-tyrosyl motif are mechanistically important. Mouse genetic model characterization; immunohistochemistry; co-transfection in eukaryotic cell line; multi-disciplinary histological and cell biological analysis Human molecular genetics High 20067920
2016 Amelogenin (encoded by Amelx) is required for thickening the enamel layer, organizing enamel ribbon development, and facilitating conversion of enamel ribbons from octacalcium phosphate into hydroxyapatite. In Amelx-null mice, enamel thickness was only 1/6th of wild type, nanohardness was less than half normal, enamel ribbons fused into plates, and the predominant mineral was octacalcium phosphate rather than hydroxyapatite. Amelx+/− mice showed lyonization-dependent enamel variation. RT-PCR, Western blotting, immunohistochemistry, transmission electron microscopy, scanning electron microscopy, nanohardness testing, X-ray diffraction; Amelx knockout mouse model Molecular genetics & genomic medicine High 27896287
2014 A silent mutation in exon 4 of AMELX that causes inclusion of exon 4 (normally almost always skipped) in the mRNA transcript leads to enamel matrix mineralization defects. Transgenic animal modeling confirmed that alteration of the conserved alternative splicing repertoire of AMELX (ratio and quantity of isoforms) causes enamel defects, demonstrating that the specific pattern of AMELX alternative splicing is mechanistically required for normal enamel formation. Family recruitment, AMELX mutation identification, mRNA splice analysis, transgenic animal model generation and characterization Journal of dental research High 25117480

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2019 The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 1770 31666701
2011 Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 611 20593411
2006 AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. The New England journal of medicine 391 17050891
2018 AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies. Cancer discovery 340 30254093
2004 AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties. The Journal of pharmacology and experimental therapeutics 325 15615864
2013 Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 283 24014831
2016 Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. Neurology 275 26879279
2006 AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer research 262 16951187
2009 Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 257 19786654
2020 Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 250 31895611
1991 A deletion in the amelogenin gene (AMG) causes X-linked amelogenesis imperfecta (AIH1). Genomics 245 1916828
2004 Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clinical pharmacology and therapeutics 231 15592334
2015 Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism. Leukemia 215 26239198
2009 Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 203 19546406
2020 AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 200 33203642
2003 The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. Journal of the American Society of Nephrology : JASN 199 12595492
2003 The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney international 171 12472790
2017 First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 170 28655795
2015 Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor. The Journal of pharmacology and experimental therapeutics 166 26559125
2013 CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood 166 24300852
2012 A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Annals of oncology : official journal of the European Society for Medical Oncology 166 22700995
2007 Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 159 17557949
2013 Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood 146 24311721
2014 Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity. Cancer cell 141 25043603
2010 Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Molecular cancer therapeutics 129 20937592
2015 The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents. Molecular cancer therapeutics 127 25567130
2009 AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Molecular cancer therapeutics 120 19366899
2007 AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clinical cancer research : an official journal of the American Association for Cancer Research 118 18006775
2014 Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. Molecular cancer therapeutics 115 24674885
1992 Identification of a nonsense mutation in the amelogenin gene (AMELX) in a family with X-linked amelogenesis imperfecta (AIH1). Human genetics 114 1483698
2019 Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release. Clinical cancer research : an official journal of the American Association for Cancer Research 112 30918018
2019 Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma. Investigational new drugs 108 31359240
2010 Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer research 108 20935223
2020 Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors. Journal for immunotherapy of cancer 105 33046621
1995 Characterisation of molecular defects in X-linked amelogenesis imperfecta (AIH1). Human mutation 102 7599636
2008 The co-crystal approach to improve the exposure of a water-insoluble compound: AMG 517 sorbic acid co-crystal characterization and pharmacokinetics. Journal of pharmaceutical sciences 100 18214948
2014 Discovery of a small molecule MDM2 inhibitor (AMG 232) for treating cancer. Journal of medicinal chemistry 94 24967612
2020 A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention. Cephalalgia : an international journal of headache 93 33231489
2012 AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. Cancer 92 22692704
2019 Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia. Blood advances 89 31253596
2024 First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration. Annals of oncology : official journal of the European Society for Medical Oncology 85 39293516
2015 AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma. Molecular cancer therapeutics 82 25931519
2011 AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents. PloS one 80 22087278
2012 Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients. The Journal of allergy and clinical immunology 79 23174659
2010 Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor. Molecular cancer therapeutics 75 20124448
2021 The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 73 33504551
2017 Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects. Pharmaceutical research 71 28593473
2018 Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors. Journal for immunotherapy of cancer 70 30253804
2000 Unique enamel phenotype associated with amelogenin gene (AMELX) codon 41 point mutation. Journal of dental research 70 11005731
2015 T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330. Blood cancer journal 69 26295610
2011 Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models. The Journal of pharmacology and experimental therapeutics 67 21385891
2020 AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing. Cell death discovery 64 32655895
2015 Critical Cysteine Residues in Both the Calcium-Sensing Receptor and the Allosteric Activator AMG 416 Underlie the Mechanism of Action. Molecular pharmacology 63 26290606
2014 Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3. Journal of medicinal chemistry 63 24641103
2025 AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted Cancers. Cancer discovery 58 39282709
2015 Evolocumab (AMG 145) for primary hypercholesterolemia. Expert review of cardiovascular therapy 58 25824308
2017 Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-γ monoclonal antibody, in SLE subjects without or with lupus nephritis. Lupus science & medicine 57 29018537
2012 Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. Annals of oncology : official journal of the European Society for Medical Oncology 55 23108953
2010 A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU international 55 21156020
2020 The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. Blood advances 54 32898244
2015 The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk. PloS one 53 26305211
2013 Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 53 24235081
2013 AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients. Kidney international 51 23903371
2012 MBL2, MASP2, AMELX, and ENAM gene polymorphisms and dental caries in Polish children. Oral diseases 50 22221294
2020 AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research 49 31937611
2015 Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 48 26304872
2015 Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. Arthritis research & therapy 47 26290435
2013 AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models. Molecular cancer therapeutics 46 23990115
2019 Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody-drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII. Cancer chemotherapy and pharmacology 45 31154523
2016 In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models. Molecular cancer therapeutics 45 27196782
2024 AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer. Cancer discovery 44 37861452
2010 Association between AMELX polymorphisms and dental caries in Koreans. Oral diseases 44 21114591
2019 89Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake. Clinical cancer research : an official journal of the American Association for Cancer Research 43 30745297
2014 Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research 43 24727326
2015 Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study. Breast (Edinburgh, Scotland) 42 25747197
2010 AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer. Current opinion in molecular therapeutics 42 20677100
2020 AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys. Blood advances 41 32886754
2010 Effect of calcium and the calcimimetic AMG 641 on matrix-Gla protein in vascular smooth muscle cells. Calcified tissue international 41 21161195
2021 Spotlight on Sotorasib (AMG 510) for KRAS G12C Positive Non-Small Cell Lung Cancer. Lung Cancer (Auckland, N.Z.) 40 34675734
2015 AMG 151 (ARRY-403), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes. Diabetes, obesity & metabolism 40 26434934
2014 Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-γ IgG1 monoclonal antibody, in patients with systemic lupus erythematosus. Pharmaceutical research 40 25213774
2019 AMG 510 First to Inhibit "Undruggable" KRAS. Cancer discovery 39 31189530
2018 A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors. Investigational new drugs 39 29980894
2016 Enamel ribbons, surface nodules, and octacalcium phosphate in C57BL/6 Amelx mice and Amelx lyonization. Molecular genetics & genomic medicine 39 27896287
2014 Inhibitors of β-site amyloid precursor protein cleaving enzyme (BACE1): identification of (S)-7-(2-fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)-5'H-spiro[chromeno[2,3-b]pyridine-5,4'-oxazol]-2'-amine (AMG-8718). Journal of medicinal chemistry 37 25363711
2009 The calcimimetic AMG 641 accelerates regression of extraosseous calcification in uremic rats. American journal of physiology. Renal physiology 37 19321594
2015 Discovery of N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), a highly selective, orally bioavailable inhibitor of aurora kinases with activity against multidrug-resistant cancer cell lines. Journal of medicinal chemistry 36 25970324
2010 A mutation in the mouse Amelx tri-tyrosyl domain results in impaired secretion of amelogenin and phenocopies human X-linked amelogenesis imperfecta. Human molecular genetics 36 20067920
1993 Technical aspects of acoustic myography (AMG) of human skeletal muscle: contact pressure and force/AMG relationships. Journal of neuroscience methods 36 8321016
2014 Alteration of conserved alternative splicing in AMELX causes enamel defects. Journal of dental research 35 25117480
2023 Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting Delta-Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC). Journal of clinical pharmacology 34 37694295
2017 Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer. Cancer 34 28472537
2012 Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme. Drug metabolism and disposition: the biological fate of chemicals 34 22517972
2010 Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis. Expert opinion on biological therapy 34 21114421
2014 Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia. Molecular cancer therapeutics 33 24526162
2020 KRAS(G12C)-AMG 510 interaction dynamics revealed by all-atom molecular dynamics simulations. Scientific reports 32 32686745
2017 A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemia. American journal of hematology 31 28370201
2013 A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecologic oncology 31 24361733
2019 Erenumab (AMG 334), a monoclonal antagonist antibody against the canonical CGRP receptor, does not impair vasodilatory or contractile responses to other vasoactive agents in human isolated cranial arteries. Cephalalgia : an international journal of headache 30 31366221
2014 Clinical pharmacology of AMG 181, a gut-specific human anti-α4β7 monoclonal antibody, for treating inflammatory bowel diseases. British journal of clinical pharmacology 30 24803302

Missed literature

Know a paper Affinage missed for AMELX? Flag it for the maintainers and the community.

No submissions yet.